Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA.
Department of Veterinary Medicine, Federal University of Paraná, Curitiba, Paraná, Brazil.
Vet Ophthalmol. 2021 May;24(3):229-239. doi: 10.1111/vop.12878. Epub 2021 Mar 7.
To investigate veterinary ophthalmologists' use of presumed neuroprotective therapies for degenerative retinal and optic nerve diseases in dogs.
An online survey was sent to 663 board-certified veterinary ophthalmologists who were Diplomates of the American College of Veterinary Ophthalmologists (ACVO), Asian College of Veterinary Ophthalmologists (AiCVO), Latin American College of Veterinary Ophthalmologists (Colegio Latinoamericano de Oftalmólogos Veterinarios, CLOVE), or European College of Veterinary Ophthalmologists (ECVO). The survey was created using Qualtrics® software and focused on the prescription of presumed neuroprotective treatments for canine glaucoma, sudden acquired retinal degeneration syndrome (SARDS), progressive retinal atrophy (PRA), and retinal detachment (RD).
A total of 165 completed surveys were received, representing an overall response rate of 25%, which was comparable across the four specialty colleges. Of all respondents, 140/165 (85%) prescribed some form of presumed neuroprotective therapies at least once in the last five years: 114/165 (69%) for glaucoma, 51/165 (31%) for SARDS, 116/165 (70%) for PRA, and 50/165 (30%) for RD. The three most recommended neuroprotective reagents were the commercial Ocu-GLO™ Vision Supplement for animals, amlodipine, and human eye supplements.
Despite lack of published clinical efficacy data, the majority of surveyed board-certified veterinary ophthalmologists previously prescribed a presumed neuroprotective therapy at least once in the last five years in dogs with degenerative retinal and optic nerve diseases.
调查兽医眼科医生在犬退行性视网膜和视神经疾病中使用假定的神经保护疗法的情况。
向美国兽医眼科医师学院（ACVO）、亚洲兽医眼科医师学院（AiCVO）、拉丁美洲兽医眼科医师学院（Colegio Latinoamericano de Oftalmólogos Veterinarios，CLOVE）和欧洲兽医眼科医师学院（ECVO）的 663 名认证兽医眼科医生发送了一份在线调查。该调查使用 Qualtrics®软件创建，重点关注犬青光眼、获得性视网膜变性综合征（SARDS）、进行性视网膜萎缩（PRA）和视网膜脱离（RD）的假定神经保护治疗处方。
共收到 165 份完整的调查问卷，总体回应率为 25%，在四个专业学院中具有可比性。在所有回答者中，140/165（85%）在过去五年中至少开过一次某种形式的假定神经保护疗法：114/165（69%）用于青光眼，51/165（31%）用于 SARDS，116/165（70%）用于 PRA，50/165（30%）用于 RD。推荐的三种最有效的神经保护试剂是商业 Ocu-GLO™ Vision Supplement for animals、氨氯地平和人眼补充剂。
尽管缺乏已发表的临床疗效数据，但在过去五年中，大多数接受调查的认证兽医眼科医生在犬退行性视网膜和视神经疾病中至少开过一次假定的神经保护治疗。
